Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

Panuveitis simulating ocular Behçet's in cases of chronic myelogenous leukaemia in remission.

BMJ Case Reports 2017 November 24
We report two patients with chronic myelogenous leukaemia (CML) in remission phase who developed panuveitis simulating Behçet's disease. A 26-year-old man presented with bilateral panuveitis (hypopyon in the right eye, bilateral anterior segment inflammation, vitritis and retinitis). He was on imatinib for CML which was in remission. He gave a history of recurrent oral ulcers. The panuveitis responded to oral and topical steroids but recurred after the steroids were stopped. His ocular condition again stabilised on restarting oral steroids and azathioprine. The second patient, a 28-year-old man, presented with bilateral anterior segment inflammation, vitritis, exudative retinal detachment and hypopyon in the right eye. He was also on imatinib with the CML being in remission. The uveitis and exudative retinal detachment improved on systemic and topical steroids. The vision of this patient did not improve as optic atrophy ensued. The panuveitis seen in our patients with CML responded favourably to oral steroids/immunosuppressant therapy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app